Merck & Co., Inc.'s new combination product for type 2 diabetes, has been granted a marketing authorisation from the European Commission (EC). 'Janumet' (sitagliptin/metformin) helps patients lower blood sugar levels to help reach their treatment goal through the efficacy of sitagliptin, a DPP-4 inhibitor, and metformin, a mainstay of diabetes therapy. Janumet has a low risk of weight gain and hypoglycaemia compared with metformin alone and targets all three key defects of diabetes: insulin deficiency from pancreatic beta cells, insulin release, and overproduction of glucose by the liver.
The details can be read here.
No comments:
Post a Comment